Hydroxychloroquine in the treatment of chronic erythema nodosum

Alloway, Jeff A.; Franks, L.K.

doi:10.1111/j.1365-2133.1995.tb08725.x

Cited by 23 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two cases of Weber‐Christian panniculitis have been shown to be treated successfully; one in a 62‐year‐old woman with oral chloroquine 250 mg daily (117), and the other was a 10‐year‐old boy being treated with hydroxychloroquine 4 mg/kg/day that allowed reduction in his systemic prednisone therapy (115). The use of hydroxychloroquine has been reported to be effective in chronic erythema nodosum (118). Recently, the use of antimalarials has been reported to treat lipoatrophic panniculitis (119).…”

Section: Clinical Use: Indicationsmentioning

confidence: 99%

New concepts in antimalarial use and mode of action in dermatology

2007

View full text Add to dashboard Cite

Although chloroquine, hydroxychloroquine and quinacrine were originally developed for the treatment of malaria, these medications have been used to treat skin disease for over 50 years. Recent clinical data have confirmed the usefulness of these medications for the treatment of lupus erythematosus. Current research has further enhanced our understanding of the pharmacologic mechanisms of action of these drugs involving inhibition of endosomal toll-like receptor (TLR) signaling limiting B cell and dendritic cell activation. With this understanding, the use of these medications in dermatology is broadening. This article highlights the different antimalarials used within dermatology through their pharmacologic properties and mechanism of action, as well as indicating their clinical uses. In addition, contraindications, adverse effects, and possible drug interactions of antimalarials are reviewed.

show abstract

Section: Clinical Use: Indicationsmentioning

confidence: 99%

New concepts in antimalarial use and mode of action in dermatology

2007

View full text Add to dashboard Cite

show abstract

“…Other therapeutic agents reported useful in the treatment of EN include hydroxychloroquine (particularly for chronic EN) (46,47), cyclosporin A, thalidomide, and systemic corticosteroids (7). As with the use of any immunosuppressive medications, an underlying infectious cause of the EN should be ruled out before therapy is instituted.…”

mentioning

confidence: 99%

Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management

Gilchrist

Patterson

2010

Dermatologic Therapy

110

102

View full text Add to dashboard Cite

Erythema nodosum is the most common type of panniculitis; it may be due to a variety of underlying infectious or otherwise antigenic stimuli. The pathogenesis remains to be elucidated, but both neutrophilic inflammation and granulomatous inflammation are implicated. Beyond treating underlying triggers, therapeutic options consist mainly of nonsteroidal anti-inflammatory drugs, symptomatic care, potassium iodide, and colchicine. Erythema induratum (nodular vasculitis) is a related but distinctly different clinicopathologic reaction pattern of the subcutaneous fat. It is classically caused by an antigenic stimulus from Mycobacterium tuberculosis but may be associated with several other underlying disorders. After appropriate antimicrobial treatment in tuberculous cases, therapy for erythema induratum is similar to options for erythema nodosum.

show abstract

“…Erythema nodosum is the most common form of panniculitis and has been reported to be effectively treated with hydroxychloroquine, particularly in chronic cases . Lupus panniculitis can be effectively treated with hydroxychloroquine, including uncommon sites such as the scalp .…”

Section: Clinical Applications In Dermatologymentioning

confidence: 99%

Hydroxychloroquine in dermatology: New perspectives on an old drug

et al. 2019

View full text Add to dashboard Cite

Hydroxychloroquine is an age-old drug whose use as an immunomodulatory agent with a low side-effect profile continues to expand. We present a review of this drug including recently updated prescribing recommendations and a summary of its clinical application in dermatology. A maximum daily dose of 5.0 mg/kg based on actual body weight and no greater than 400 mg is advised in order to reduce the risk of retinopathy, which is potentially permanent and has an estimated prevalence of 7.5% at 5 years on standard dosing. Baseline ophthalmologic assessment followed by annual screening after 5 years is recommended; however, closer monitoring should be considered in the setting of existing retinopathy, a cumulative dose > 1000 g or renal dysfunction. Hydroxychloroquine is now considered to be safe in pregnancy, and routine glucose-6-phosphate dehydrogenase (G6PD) deficiency testing is not required. Smoking can significantly decrease its efficacy although the reason is still uncertain. Hydroxychloroquine appears to also demonstrate antineoplastic and cardioprotective benefits.

show abstract

Hydroxychloroquine in the treatment of chronic erythema nodosum

Cited by 23 publications

References 8 publications

New concepts in antimalarial use and mode of action in dermatology

New concepts in antimalarial use and mode of action in dermatology

Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management

Hydroxychloroquine in dermatology: New perspectives on an old drug

Contact Info

Product

Resources

About